Patent ID: 11867695
Assignee: CYTOMX THERAPEUTICS, INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC G  A  C | IPC A  C  G

Claim 14:
15. The method of claim 1, wherein the AB is an antibody that binds to a target selected from the group consisting of: 1-92-LFA-3, Anti-Lewis-Y, Apelin J receptor, APRIL, BAFF, C5 complement, C-242, CD2, CD3, CD9, CD11a, CD19, CD20, CD22, CD25, CD28, CD30, CD33, CD40, CD40L, CD41, CD44, CD47, CD52, CD56, CD64, CD70, CD80, CD86, CD95, CD117, CD132, (IL-2RG), CD133, CD137, CD138, CD172A, CEACAMS (CEA), CEACAM6 (NCA-90), CLAUDIN-3, CLAUDIN-4, cMet, Collagen, Cripto, CSFR, CSFR-1, CTLA-4, CTGF, CXCL10, CXCL13, CXCR1, CXCR2, CXCR4, CYR61, DL44, DLL4, DPP-4, EGFR, Endothelin B receptor (ETBR), EpCAM, EPHA2, ERBB3, F protein of RSV, FAP, FGF-2, FGF8, FGFR1, FGFR2, FGF43, FGFR4, Folate receptor, G-CSF, G-CSFR, GLUT1, GLUT4, GM-CSF, GM-CSFR, GP IIb/IIIa receptors, Gp130, GPNMB, HER2/neu, HGF, hGH, Hyaluronidase, IFNalpha, IFNbeta, IFNgamma, IgE, IgE Receptor (FccRI), IGF, IGF1R, IL1B, IL-1R, IL2, IL11, IL12, IL12p40, IL-12R, IL-12Rbeta1, IL13, IL13R, IL15, IL17, IL18, IL21, IL23, IL23R, IL27/IL27R (wsx1), IL29, IL-31R, IL31/IL31r, IL2r, IL4, IL4R, IL6, IL6R, Insulin Receptor, Jagged Ligands, Jagged 1, Jagged 2, LIF-R, MRP4, MUC1, Mucin-16, Na/K ATPase, Neutrophil elastase, NGF, Nicastrin, Notch Receptors, Notch 1, Notch 2, Notch 3, Notch 4, NOV, OSM-R, PAR2, PDGF-AA, PDGF-BB, PDGFRalpha, PDGFRbeta, PD-1, PD-L1, PD-L2, Phosphatidyl-serine, P1GF, PSCA, PSMA, RAAG12, RAGE, SLC44A4, Sphingosine 1 Phosphate, TGFbeta, TLR2, TLR4, TL46, TLR7, TLR8, TLR9, TNFalpha, TNFR, TRAIL-R1, TRAIL-R2, Transferrin, Transferrin receptor, TRK-A, TRK-B, uPAR, VCAM-1, VEGF, VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGFR1, VEGFR2, VEGFR3, WISP-1, WISP-2, WISP-3, Alpha-4 integrin, Alpha-V integrin, and alpha4beta1 integrin, or an antigen binding fragment of said antibody that binds to a target selected from the group of targets.